25 citations
,
May 2003 in “Expert Opinion on Therapeutic Patents” Steroid Sulfatase inhibitors show promise in treating hormone-dependent disorders like cancers, hair loss, and acne, with 667COUMATE being a potential candidate for breast cancer treatment trials.
4 citations
,
May 2019 in “Zeitschrift für Naturforschung C” Ishige sinicola extract helps bone-building cells grow and mature, which could aid in treating osteoporosis.
17 citations
,
December 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists found new, better-working inhibitors for a hormone-related enzyme.
December 2015 in “Endocrinology and Metabolic Syndrome” 20 citations
,
May 2023 in “Cancer Nanotechnology” The new drug delivery system effectively targets lung cancer cells.
5 citations
,
July 1987 in “European Journal of Obstetrics & Gynecology and Reproductive Biology” The treatment temporarily improved symptoms of hyperandrogenism in adolescents.
67 citations
,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
111 citations
,
August 2002 in “Journal of Medicinal Chemistry” New compounds were made that block an enzyme linked to breast cancer better than existing treatments.
January 2011 in “Yearbook of Endocrinology” COCs often cause nausea, vomiting, and hair loss, while Depo-Provera is linked to weight gain.
January 2007 in “Inpharma Weekly” Dutasteride is more effective for male pattern baldness than finasteride, and black cohosh extract BNO 1055 is as effective as conjugated estrogens in treating postmenopausal symptoms, with added benefits in reducing sweating and mental symptoms.
January 2024 in “Wiadomości Lekarskie” Using a protocol with LH improves pregnancy rates in patients with low ovarian reserve.
1 citations
,
September 2001 in “PubMed” ONO-3403 effectively reduces mouse skin tumor growth without side effects.
88 citations
,
June 2016 in “Human Reproduction Update” New hormonal contraceptives are safer, have fewer side effects, and offer health benefits for women.
February 2010 in “Journal of The American Academy of Dermatology” Posaconazole is a promising new treatment for toenail fungus.
May 1963 in “American journal of obstetrics and gynecology” Injecting 2 ml of TEEV every 4 weeks is better because it has the same benefits but fewer side effects.
January 2025 in “International Journal of Pharmacology” Both steroids, especially cyproterone acetate, harm quail's vital organs.
2 citations
,
March 2005 in “Journal of the American Academy of Dermatology” Equol may help with antiaging and skin health by boosting collagen and blocking certain hormones.
The FDA did not approve a testosterone drug because of safety concerns.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
June 2003 in “Obstetrical & Gynecological Survey” Postmenopausal ovary stromal cells have a unique makeup and limited steroid production, suggesting androgens come from the adrenal gland.
Nizoral improved menstrual cycles and reduced hair growth in patients with hyperandrogenism.
May 2024 in “Reactions weekly” 6 citations
,
August 2024 in “The Journal of Dermatology” Ozenoxacin reduces sebum production, helping manage acne.
2 citations
,
December 1994 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.
13 citations
,
May 2007 in “Journal of Endocrinology” Synthetic 19-norprogestins promote bone cell growth and function through their non-phenolic metabolites.
3 citations
,
July 2019 in “Case Reports in Obstetrics and Gynecology” A young woman's rare ovarian tumor was successfully removed, improving her hormonal symptoms.
September 2016 in “Journal of dermatological science” The OVOL1-OVOL2 axis is important for hair follicle differentiation and can help diagnose certain hair-related tumors.
20 citations
,
April 2009 in “Fertility and Sterility” July 2024 in “Reactions Weekly”